Aerts, Joachim

Institution/Organization
Erasmus University Medical Center

Primary Specialty
Pulmonary Medicine

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
Agree

Disclosure of Potential Conflicts
Read and understood

COI Disclosure

Disclosures
Amphera: advisor and stock owner and performance of clinical trials
Eli-Lilly: speaker and research funding
MSD: speaker and advisor
AstraZeneca: advisor
BIOCAD: speaker and DSMB member
BMS: advisory board
Genmab: steering co member

COI Disclosure Certification
Disclosed

Confidentiality Agreement
Agree

Standards of Conduct Agreement
Understand and agree

IASLC's Tax-Exempt Status
**COI Follow-Up**

Disclose any clinical trials you are conducting for institution fees.

- SPI-POZ study: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1).

- ETOP CHESS: A multicentre single arm phase II trial assessing the efficacy of radical immunotherapy and chemotherapy, stereotactic radiotherapy and surgery in patients with synchronous oligo-metastatic NSCLC.

- LIBRETTO-431 (Lilly): A multicenter, randomized, open-label, phase 3 trial comparing LOXO-292 to platinum-based and pemetrexed therapy with or without pembrolizumab as initial treatment of advanced or metastatic RET fusion- positive non-small cell lung cancer.

- Sapphire (MIRATI therapeutic): A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy.

- Daiichi Sankyo Tropion lung01: Phase 3 randomized study of DS-1062A versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer without actionable genomic alterations, protocol number DS1062-A-U301

- Daiichi Sankyo Tropion 05: Phase 2, multicenter, randomized, open-label study of DS-1062a in advanced or metastatic non-small cell lung cancer with actionable genomic alterations and previously treated with kinase inhibitor therapy and platinum-based chemotherapy with or without immunotherapy DS1062-A-U202


- EORTC 1825 (Alkaline): Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor.

- EORTC 1525: Single-arm, phase II study of nivolumab in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy – (NIVOTHYM)

- Roche MO41552 Entrectinib: Randomized, open label, multicenter, phase III study of entrectinib versus crizotinib in patients who have nonsmall cell lung cancer harboring ros1 gene rearrangements with and without central nervous system metastases.


- Start TKI: ProSpecTive sAmpling in dRiver muTation pulmonary oncology patients one Tyrosine Kinase Inhibitors (START-TKI).
- Satin studie: Safety of TKI concurrent with cranial radiotherapy in NSCLC patients; the SATIN platform trial

- Orchard studie (AstraZeneca): Biomarker-Directed, Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease Has Progressed on First-Line Therapy with Osimertinib (Tagrisso) to Assess the Safety, Tolerability, and Efficacy of Different Treatment Options for Patients Following Epidermal Growth Factor Tyrosine Kinase Inhibitor (ORCHARD).

- ImmunoSABR: Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer.

- NutriCim: The effects of an oncology tailored nutritional intervention on the bioavailability and immune-activity of PD-1 immune checkpoint inhibitors in patients with lung cancer

- TEIPP studie: T-cell Epitopes associated with Impaired Peptide Processing (TEIPP)-targeting immunotherapy in patients with relapsed advanced non small cell lung cancer (NSCLC)

- ENSURE: dENdritic cell therapy combined with SURgEry in mesothelioma

- Achiles studie: A randomized phase II study comparing atezolizumab after concurrent chemo-radiotherapy with chemo-radiotherapy alone in limited disease small-cell lung cancer

- Checkmate 777: A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer

- Amgen 20190009: A phase 3 multicenter, randomized, open label, active-controlled, study of AMG 510 versus docetaxel for the treatment of previously treated locally advanced and unresectable or metastatic NSCLC subjects with mutated KRAS p. G12C

- Skyscraper: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab plus carboplatin and etoposide with or without tiragolumab (anti-tigit antibody) in patients with untreated extensive-stage small cell lung cancer

- Denim: A Randomized, Open-Label Phase II/III Study with Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects with Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy

- Caspian: A phase III, randomized, multicenter, open-label, comparative study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for the first-line treatment in patients with extensive disease (stage IV) small-cell lung cancer

- BMS 6 (CA209817): A Phase IIIb/IV safety trial of flat dose nivolumab in combination with ipilimumab in participants with advanced malignancies

- BMS 7 (CA209743): a phase III, randomized, open label trial of Nivolumab in combination with ipilimumab versus pemetrexed with cisplatin or carboplatin as first line therapy in unresectable pleural mesothelioma
- **NVALT 24**: a phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer

- **Afacet**: Phase II study of Afatinib in combination with Cetuximab in EGFR exon 20 insertion positive non-small-cell lung cancer

- **Prima**: Prospective tumor sampling in oncology patients with solid tumors treated with Immune Modulating Agents

- **Ultima**: Prospective sampling in intravenously treated oncology patients: Immune Modulating Agents

- **Lorlatinib**: Lorlatinib neurocognitive adverse events: how to improve patient care

**Disclosure**: None

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

None

**Are you conducting clinical trials with any oncology equipment companies?**

No